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Reprogramming methodologies have provided
multiple routes for achieving pluripotency. However,
pluripotency is generally considered to be an almost
singular state, with subtle differences described
between induced pluripotent stem cells (iPSCs) and
embryonic stem cells (ESCs). We profiled miRNA
expression levels across 49 human cell lines,
including ESCs, iPSCs, differentiated cells, and
cancer cell lines. We found that the resulting miRNA
profiles divided the iPSCs and hESCs examined into
two distinct categories irrespective of the cell line
origin. The miRNAs that defined these two pluripo-
tency categories also distinguished cancer cells
from differentiated cells. Transcriptome analysis
suggested that several gene sets related to p53
distinguished these categories, and overexpression
of the p53-targeting miRNAs miR-92 and miR-141
in iPSCs was sufficient to change their classification
status. Thus, our results suggest a subdivision of
pluripotent stem cell states that is independent of
their origin but related to p53 network status.
INTRODUCTION
The progeny of pluripotent cells have the bifurcating fates of self-
renewal and differentiation into all three germ layers. The ability
to induce pluripotency in the laboratory (Takahashi and Yama-
naka, 2006) has raised the issue of criteria for the achievementCelof pluripotency. In mouse iPSCs the ability of tetraploid cells to
make a mouse satisfies quite stringent criteria (Kang et al.,
2009; Zhao et al., 2009; Boland et al., 2009); however, even
among such mice, questions about their vulnerability to disease
could point to a less than ideal pluripotent state. The problem is
more difficult in the case of human ESCs (hESCs) where the
option of tetraploidy approaches does not exist. Underlying
these considerations is the question of whether pluripotency
represents a singular state.
miRNAs provide a useful entre´e to this issue because they are
highly accurate markers of cell identity (Monticelli et al., 2005;
Aboobaker et al., 2005; Laurent et al., 2008). Their profiles unam-
biguously distinguish cell types, including ESCs, a vast variety of
precursor cells, terminally differentiated cells, and tumor types,
even among closely related cancers (Lu et al., 2005). miRNAs
play important functional roles in stem cells (Martinez and Greg-
ory, 2010) including the regulation of pluripotency (Xu et al.,
2009) and self-renewal (Melton et al., 2010).
Two reports have described a small number of differences in
miRNA patterns for human iPSCs and hESCs (Chin et al.,
2009; Wilson et al., 2009). Among the 10–12 differentially
expressed miRNAs were some ESC-specific miRNAs. The
observed differences in iPSCs at the mRNA level were partially
corrected upon extended culturing in vitro, which was inter-
preted as ongoing ‘‘reprogramming’’ in culture (Chin et al.,
2009). The authors concluded that the reprogramming process
does not drive fibroblasts to a state identical to ESCs. The
same issue was addressed by comparing the messenger and
miRNA expression patterns of genetically identical mouse
ESCs and iPSCs (Stadtfeld et al., 2010). They were indistinguish-
able except for the abnormal silencing of the Dlk1-Dio3 locus in
most iPSC clones. Derepression of that locus favored the gener-
ation of high-grade chimeras and viable all-iPSC mice.l Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Inc. 671
Table 1. Pluripotent Cell Lines Used in the Study
Cell Line Type Reprogramming Method Reference
H1 hESC Yu et al., 2007
H7 hESC Yu et al., 2007
H9 hESC Thomson et al., 1998
H14 hESC Yu et al., 2007
HES03 hESC Crook et al., 2007
HES04 hESC Crook et al., 2007
iPS(CCD)-1 iPSC virus (O, S, L, N) Yu et al., 2007
iPS(CCD)-2 iPSC virus (O, S, L, N) Yu et al., 2007
iPS(IMR90)-3 iPSC virus (O, S, L, N) Yu et al., 2007
iPS(IMR90)-4 iPSC virus (O, S, L, N) Yu et al., 2007
ADA-iPS3 iPSC virus (O, S, K, M) Park et al., 2008a
MRC5-iPS7 iPSC virus (O, S, K, M) Park et al., 2008b
hFib2-iPS5 iPSC virus (O, S, K, M) Park et al., 2008b
dH1f-iPS#8 iPSC virus (O, S, K, M) Chan et al., 2009
dH1f-iPS#9 iPSC virus (O, S, K, M) Chan et al., 2009
HNF-iPS-P01 iPSC protein (O, S, K, M) Kim et al., 2009
HNF-iPS-P02 iPSC protein (O,S,K,M) Kim et al., 2009
HNF-iPS-Vir iPSC virus (O, S, K, M) Kim et al., 2009
iPS-DF-19.9-7T iPSC episome (O, S, N, L, K,M, SV) Yu et al., 2009
iPS-DF-19.11 iPSC episome (O, S, N, L, K,M, SV) Yu et al., 2009
iPS-DF-4.7 iPSC episome (O, S, N, L, K,M, SV) Yu et al., 2009
iPS-DF-6.9 iPSC episome (O, S, N, L, K,M, SV) Yu et al., 2009
Abbreviations: O, OCT4; S, SOX2; L, LIN28; N, NANOG; K, KLF4; M, MYC; SV, SV40LT.
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miRNAs Define Two p53-Linked Pluripotent StatesThe inherent inefficiency of reprogramming has also raised
interest in the nature of reprogramming failures and partially
reprogrammed cells. The transition to a fully reprogrammed
state by enforced expression of transcription factors in
somatic cells is best predicted by proviral silencing and
expression of TRA-1-60, DNMT3B, and REX1 (Chan et al.,
2009). A compelling synthesis of these views is the finding
that reprogramming is a continuous stochastic process where
all mouse donor cells have the capacity to generate iPSCs with
continued growth and transcription factor expression (Hanna
et al., 2009).
Here we profiled miRNA expression in a large number of
human pluripotent cells of hESC or iPSC origin to test the
hESC/iPSC divide and the variability of the pluripotent state.
We also profiled differentiated and cancer cells as a gauge
of the variation in miRNA expression and used all of these
data to construct a miRMap. We found that the variability of
miRNA expression in human iPSCs and hESCs was compa-
rable to the variability among all the profiled differentiated
and cancer cells. Strikingly, we identified two distinct cate-
gories of pluripotent cells that are not related to cellular origin.
Instead, these two pluripotent stem cell states differ in the
expression of a group of miRNAs that also classify cancer cells
and in the status of their p53 network. Overexpression of the
p53-regulatory miRNAs miR-92 and miR-141 in iPSCs induced
a change of miRNA profile class. We also found that it is
possible to examine differentiation and reprogramming in
a quantitative way by using cellular miRNA profiles and the
miRMap.672 Cell Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier IncRESULTS
miRNA Profiles Distinguish Two Categories
of Pluripotent Cells
We profiled 330 miRNAs, and for some samples an expanded
set of 466 miRNAs via multiplexed RT-PCR in 6 hESC lines,
16 iPSC lines, 6 differentiated cells (fibroblasts, fetal and adult
brain, lung tissue), 9 cancer lines (from colon, pancreas, liver,
and brain tissues), and 12 glioma biopsies (Figure S1 available
online). The iPSCs were generated by different sets of reprog-
ramming factors and different delivery methods (virus
[Yu et al., 2007; Park et al., 2008b, 2008a; Chan et al., 2009],
episome [Yu et al., 2009], or proteins [Kim et al., 2009];
Table S1) in ten reprogramming experiments from different
groups with human fibroblasts that differed in age and gender.
The fibroblasts used were fetal (MRC5, IMR90), newborn
(CCD-1079sk and HNF), adult (from normal donor [hFib2] or
disease-specific [ADA]), or fibroblasts derived through in vitro
differentiation of hESCs (dH1f) (Table 1). The data set obtained
contained 308 detected miRNAs exhibiting up to 106-fold
change in expression among the 49 samples (Figure 1A). We
used nonnegative matrix factorization (NMF) (Lee and Seung,
1999) as an unsupervised way to identify miRNA profile clusters
among pluripotent, differentiated, and cancer cells. The NMF-
transformed miRNA profiles from these cell types distinguished
four clusters with only three metaprofiles (Experimental Proce-
dures). We expected to find three clusters corresponding to
pluripotent, differentiated, and cancer cells. Surprisingly, we
instead found that pluripotent cells formed two distinct clusters.
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Figure 1. miRNA Expression Distinguishes Two Kinds of Pluripotent Cells, Cancer, and Differentiated Cells
(A) Comparison of the relative expression levels of 308 miRNAs in 6 hESC lines; 16 human iPSC lines reprogrammed with virus, episomes, or proteins; 6 differ-
entiated cells; 9 cancer lines; glioma biopsies. Cell lines and miRNAs expression were clustered via average hierarchical clustering with Pearson’s correlation
coefficient as a distance.
(B) Consensus clustering of pluripotent cells, cancer, and differentiated cells by NMF with three metaprofiles. The NMF-transformed miRNA profiles from plurip-
otent, cancer, and differentiated cells distinguished four clusters.
(C) The first three PCs clustered cells in the four categories identified by NMF.
See also Figure S1.
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miRNAs Define Two p53-Linked Pluripotent Statesthat did not respect the origin of these cells as either iPSCs or
hESCs (Figure 1B). One cluster consisted of most hESCs and
some virus-induced iPSCs and the other cluster consisted of
protein-, episome-, and some virus-induced iPSCs and one
hESC line, H9 (Figure 1B) Thus, pluripotent cells, whether iPSCs
or embryo derived, had a fundamental difference that does not
depend on whether they were reprogrammed from a somatic
cell or came from an embryo.CelTo understand the relationship between the four clusters, it is
useful to examine projections on suitably chosen directions in
the space spanned by miRNA expression patterns. This can be
accomplished with the help of principal component analysis
(PCA). Like NMF, PCA was also able to capture miRNA expres-
sion in a low dimensional space; indeed, three principal compo-
nents (PC) were sufficient to identify the four clusters (Figures 1C
and 1D). The top PC, PC1 (64.7% of the variation in miRNAl Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Inc. 673
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Figure 2. Expression Levels of Pluripotency- and Differentiation-Associated miRNAs in Individual Pluripotent Lines
Relative median expression levels of miRNAs belonging to the miR-302 family (A), the miR-371/372/373 family (B), the miRNA cluster on chromosome 19q13.42
(C), and the let-7 family (D) in individual pluripotent cells. For each miRNA family, we computed the relative median expression compared to the hESC line H1
across miRNAs belonging to that family.
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miRNAs Define Two p53-Linked Pluripotent Statesexpression), was characterized by small contributions from
a large number of miRNAs. PC1-associated miRNAs were char-
acterized by miRNAs that are overexpressed in cancer cells
compared to differentiated cells. For example, the miR-17–92
cluster (He et al., 2005) falls in PC1. The second and third PCs,
PC2 and PC3 (13.3% and 5.0% of the variation, respectively),
appeared to define a plane where the four clusters identified
by NMF were well delineated. Because PC2 contained miRNAs
associated with pluripotency, it was not surprising that PC2
discriminated pluripotent cells from all other cells. Interestingly,
PC3 distinguished the two categories of pluripotent cells as
well as cancer cells from differentiated cells (Figure 1D). This
result shows that one of the pluripotent cell clusters shares an
miRNA signature with cancer cells. PC1, PC2, and PC3 repre-
sented 83% of the variation among all those samples, so how
miRNA profiles of pluripotent cells project on that subspace is
an excellent gauge of their diversity. The projection of pluripotent
cell miRNA profiles had a spread along PC1 and PC3, compa-
rable to the combination of differentiated and cancer cells.
Notably, there were no marked differences between iPSCs and
hESCs if one accounts for the smaller hESC sample size. iPSC
lines did not segregate by gender, nor by the set of reprogram-
ming factors used to derive them. Culture conditions such as
FGF concentration or feeder cells also had no significant influ-
ence on miRNA profiles (data not shown).
Human iPSCs have been reported to differ from hESCs in the
expression of some hESC-specific miRNAs (Wilson et al., 2009;
Chin et al., 2009). We therefore looked specifically at those
miRNAs reported to differ between hESCs and hiPSCs, which
include miR-302, miR-371 families, and the chromosome
19q13.42 miRNA cluster, all associated with pluripotency, and
at the let-7 family associated with differentiation. We did not
observe a systematic trend distinguishing iPSCs from hESCs.
Specifically, the four miRNAs assessed from themiR-371 cluster
exhibited the largest changes in expression: most of the iPSCs
lines and two hESCs had an overall 10-fold lower expression
compared to the other hESCs, the protein-induced iPSCs, and
one virus-induced iPSC (Figure 2A). Expression of 6 miRNAs
from the miR-302 family and 33 miRNAs from the chromosome
19q13.42 cluster was stable across pluripotent cells apart from
a few outliers (Figures 2B and 2C). Virus-induced iPSCs showed
expression of nine miRNAs from the let-7 family similar to those
of hESCs (Figure 2D), but this family was further downregulated674 Cell Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Incby 30-fold in episome-induced iPSCs. One protein-induced
iPSC line failed to downregulate the expression of let-7 family
and therefore had expression levels comparable to those of
fibroblasts. In contrast, the iPSCs that clustered with H9 hESC
sharedwith cancer cells the expression profile of a set of a dozen
miRNAs (Figure 1D). Overall the set of pluripotent cells could not
be further classified by the expression levels of pluripotency-
associated miRNAs. Rather, pluripotent cells exhibited large
changes in expression of miRNAs, some of which are not linked
with pluripotency. The miRNAs that did classify pluripotent cells
belonged to the set that clusters cancer cells from differentiated
cells.
Two Maximum Margin Classifiers Define the Four
Categories of miRNA Profiles
Unbiased classification separated cancer, differentiated cells,
and two pluripotent categories, but this approach is not optimally
adapted to assess how additional data will fit with respect to the
four clusters. We therefore used supervised learning methods to
construct two linear classifiers, r1 and r2 (see Experimental
Procedures), to find the optimal separation of the four clusters.
Classification was then carried out by projecting miRNA profiles
on those directions. Four categories of cells were thus deter-
mined: (1) differentiated cells, (2) cancer cells, (3) a set of plurip-
otent cells comprising most hESCs and some virus-derived
iPSCs, and (4) another set of pluripotent cells with episome-
and protein-derived iPSCs and some virus-derived iPSCs and
one hESC line. Classifier r1 separated categories 1 and 3 from
categories 2 and 4; classifier r2 separated categories 1 and 2
from 3 and 4, i.e., pluripotent cells from lineage-committed cells
(Figure 3A). Classifier r1 was driven by the on/off expression of
miR-484, miR-486, miR-361, miR-7, miR-199a*, miR-302a,
miR-301, miR-450, miR-382, miR-375, and miR-452. These
miRNAs were not detected in categories 2 and 4. Classifier r2
was driven largely by the expression of the miR-302 family,
miR-371/372 (the miRNA cluster on chromosome 19q13.42),
and miR-18b (Figure 3B). All those miRNAs had a much higher
expression in pluripotent cells compared to lineage-committed
cells. r2-associated miRNAs have their promoters occupied by
OCT4 in hESCs except for the miRNA cluster on chromosome
19q13.42 (Marson et al., 2008). The classifiers were robust
with respect to data resampling. We use classifiers r1 and r2
to define miRMap, a 2D classification of human miRNA profiles..
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Figure 3. Two Linear Classifiers Distinguish
Fundamental miRNA Profiles
(A) Projection of miRNA profiles on two linear clas-
sifiers r1 and r2 that separated four categories
of miRNA profiles. Classifiers r1 and r2 define
miRMap.
(B) miRNAs contributing to the two classifiers.
miRNAs associated with classifier r1 were not de-
tected in the cells belonging to categories 2 and 4.
miRNAs associated with classifier r2 were not de-
tected in lineage-committed cells (miR-18b was
expressed at low levels in some differentiated cells
and cancer lines).
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miRNAs Define Two p53-Linked Pluripotent StatesMultiple Microarray Analyses Validate the miRMap
We tested the robustness of miRMap and the existence of the
two categories of pluripotent cells by applying the two linear
classifiers r1 and r2 to published microarray data (Lu et al.,
2005; Ach et al., 2008; Laurent et al., 2008; Chin et al., 2009;
Stadler et al., 2010). We assessed the classifier r1 with profiles
of tumors and normal samples from Lu et al. (2005) (Figure 4A).
Projection on this classifier separated cancer lines from normal
tissue with 98% accuracy. Classification of tumor samples was
less robust with 70% accuracy probably resulting from the
heterogeneity of tumor tissues. We assessed the classifier r2
with profiles of hESCs and differentiated cells from Laurent
et al. (2008) (Figure 4B). Projection on this classifier separated
perfectly hESCs from differentiated cells. Not surprisingly, differ-
entiated hESC samples projected in a similar way as differenti-
ated cells.
The small dynamic range of detection or the absence of
probes associated with miRMap classifiers prevented us from
obtaining meaningful projections of some microarray data sets
onto miRMap. We could map on miRMap miRNA profiles of
iPSCs (Chin et al., 2009), profiles of undifferentiated and differen-
tiating hESCs (Stadler et al., 2010), as well as profiles of a variety
of differentiated cells (Figure 4C; Ach et al., 2008). Different
studies could be efficiently combined because a relatively large0.5
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Figure 4. Robustness of miRMap to Microarray Data
(A) Projection on classifier r1 of miRNA profiles of tumors and normal samples fro
excellent.
(B) Projection on classifier r2 of miRNA profiles of hESCs and differentiated cells
(C) Projection on miRMap of miRNA profiles of iPSCs, hESCs, differentiated cell
platforms, GPL6955 for Ach et al. (2008) and Stadler et al. (2010) and GPL8941
(D) Comparison of the miRMap categories defined via projections of miRNA p
The larger separation between classes in the RT-PCR case is due to the larger d
Celnumber of miRNAs contributed in a comparable way to the clas-
sifiers r1 and r2. Pluripotent cells formed two distinct categories
along classifier r1. We compared them to the location of the
categories drawn from our RT-PCR data. We found that they
essentially overlapped. The larger separation between cate-
gories in our own data set was probably due to the increased
detection range of RT-PCR compared tomicroarrays. Therefore,
the miRNA-based classifiers r1 and r2 can be applied to pub-
lished microarray data and the published data supported the
existence of two categories of human pluripotent cells.
The Two Pluripotency Categories Differ in the State
of the p53 Network
To investigate the nature of the twomiRMap categories of plurip-
otent cells, we used transciptome data from pluripotent cells (Yu
et al., 2007) to perform GSEA analysis (Subramanian et al., 2005)
including canonical pathways, BioCarta, GenMAPP, and KEGG
gene sets and the cancer modules from the computational
gene set (Segal et al., 2004). The pluripotent cell transcriptomes
from Yu et al. (2009) were hESCs belonging to category 3 and
episome-derived iPSCs belonging to category 4. We found
that the gene sets for p53 pathway, apoptosis, cell cycle, IL-1
pathway, and N-glycan metabolism were enriched in category
4 cells compared to category 3 cells (FDR < 0.25). The p53hESC
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for Chin et al. (2009). Pluripotent cells form two distinct clusters.
rofiles from our RT-PCR data (blue) or from published microarray data (red).
etection range of the technique compared to microarrays.
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Figure 5. p53 KO or Overexpression of miR-92 and miR-141 Influence the Projection of miRNA Profiles along Classifier r1
(A) Genes in the p53 pathway, which expressionwas significantly different (gray) in episome-induced iPSC lines compared to hESCs. The p53 pathway is adapted
from KEGG (http://www.genome.jp/kegg/).
(B) miRNA expression profiles of mouse embryonic fibroblasts (MEFs), p53/MEFs, p53/ Tsc2/MEFs, and mouse cancer lines were projected on PC1 and
classifier r1. Squares, mouse cells; circles, human cells; diamonds, human fibroblasts; black, differentiated cells; orange, cancer lines.
(C) iPSCs with ectopic expression of miR-92 and miR-141 had miRNA expression profiles that belonged to category 4.
(D) Ectopic expression in iPS(CCD)-2 of miR-92 and miR-141, which target p53 shifted significantly the miRNA profile along PC1. Projections of MEF and p53/
(p53 KO) MEF miRNA profiles are also indicated.
See also Figures S2 and S3.
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miRNAs Define Two p53-Linked Pluripotent Statespathway, apoptosis, and the cell cycle are all linked. Two-thirds
of the genes in the p53 pathway were significantly dysregulated
in category 4 cells compared to category 3 cells (Figure 5A),
a significant enrichment compared to a random set (p < 105,
see Experimental Procedures). Among those genes were regula-
tors of the cell cycleCDKN2A (encoding p16INK4A and p14ARF)
andCDKN1A (p21) and a number of caspase activators. We also
found an enrichment of genes under the transcriptional control of
p53 (Riley et al., 2008) (p = 106).
These computational results might be explained by a differen-
tial expression of p53 between the two categories of pluripotent
cells. We therefore checked p53 transcript levels from 13 iPSCs
belonging to categories 3 and 4. Compared to category 3 iPSCs,
category 4 iPSCs showed a 2-fold decrease (p < 0.05, t test) (Fig-
ure S2). We therefore hypothesized that gene expression within676 Cell Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Incthe p53 network might influence the miRNA profile of cells and
may be critical to determine its category along classifier r1.
To test this hypothesis, we used mouse cells with defined alter-
ations in the p53 network, specifically mouse embryonic fibro-
blasts (MEFs), which are p53, p53/MEFs, and p53/Tsc2/
MEFs (Zhang et al., 2003). We restricted our analysis to 167
miRNAs that are conserved between human and rodent. The
MEF miRNA profile was classified with human fibroblasts
in category 1 (Figure 5B). The profiles of p53/ MEFs and
p53/Tsc2/ MEFs localized in category 2 with the human
and mouse cancer cells. The change of category was accompa-
nied by additional changes in miRNA expression: indeed, those
profiles were shifted along the first principal component (PC1),
which represented most of the variation in miRNA expression,
toward the cancer lines compared to MEF (p < 0.05; Figure 5B)..
PC1
CB
fibroblast
type I/type II
type III (iPSCs)
minimum shifts
for p<0.05:
A Directed differentiationto retinal progenitors
iPS
(CC
D)-
2
starting iPSC
DIV 4
DIV 7
DIV 10
iPS
(CC
D)-
1
minimum shifts
for p<0.05:
(category 2)
(category 3)(category 4)
fibroblast
type I/type II
type III (iPSCs)
minimum shifts
for p<0.05:
(category 2)
(category 1)
(category 4)
Partially reprogrammed cells Partially reprogrammed cells
differentiated
cancer
1
2
1
2 2
Figure 6. miRMap Tracks Cellular States during Differentiation Procedures and Reprogramming
(A) miRNA expression was profiled at different stages (DIV 4, 7, and 10) along directed differentiation of iPS(CCD)-1 and -2 to retinal progenitors (Lamba et al.,
2006), a multipotent state, and projected on miRMap.
(B) miRNA expression was profiled in partially reprogrammed cells as well as in iPSCs generated concomitantly (Chan et al., 2009) and projected on miRMap.
Type I and II cells, which lack hESC markers, shared the same miRNA signature as multipotent stem cells with various degrees of expression of pluripotency-
associated miRNAs.
(C) Projection of the miRNA profiles of partially reprogrammed cells on PC1 to assess the expression of the majority of the miRNAs. Partially reprogrammed cell
profiles projected on the cancer side.
See also Figure S4.
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sufficient to change the miRNA expression category of MEFs.miR-92 and miR-141 Overexpression Broadly Alters
the miRNA Profile of iPSCs
Because p53 KO changed the category of miRNA profiles
among murine lineage-committed cells, overexpression of
miRNAs predicted to target p53 in human category 3 iPSCs
could phenocopy this category change. We chose two miRNAs
predicted to target p53, miR-92, and miR-141. miR-92 is
a member of the miR-17–92 cluster, which shows increased
expression in cancer (He et al., 2005). miR-141 exhibited a large
variation of expression among cancer cells. First we validated
that p53was a target of miR-92 andmiR-141(Figure S3). Overex-
pression of miR-92 or miR-141 with lentivirus in iPS(CCD)-2 led
to a 2-fold decrease in p53 transcript levels compared to iPS
(CCD)-2 controls (Figure S2).
Overexpression of miR-141 induced at least a 4-fold change in
expression of 165 miRNAs compared to the control iPS(CCD)-2
cells. 80 of those also changed in the lines infected with lentivirus
overexpressing miR-92. The levels of 67 miRNAs changed more
than 1000-fold. Overexpression of miR-517a (a pluripotency-
associated miRNA that has no apparent cancer-related
predicted targets) (Grimson et al., 2007) or control lentivirus
infection had no effect (data not shown). We projected the
miRNA expression profiles of the infected lines onto the miRMap
and PC1 to assess whether these variations in miRNA expres-
sion were quantitatively similar to those induced by p53
knockout (KO) in MEFs. The profiles of all the iPSC lines infected
with lentivirus overexpressing miR-92 or miR-141 fell into cate-
gory 4, whereas the profile of the parental iPSCmapped to cate-
gory 3 (Figure 5C). These cells were also shifted compared to the
parental iPSC(CCD)-2 profile along PC1 similarly to p53 KO inCelMEF (p < 0.05; Figure 5D). The p53 network was therefore central
in determining the projection along classifier r1.miRMap Tracks Differentiation Procedures
and Reprogramming
Wesought to probemiRNAprofiles of cells as they transition from
one state to another during differentiation or according to reprog-
ramming procedures. We differentiated the hESC line H9 to
neurons (Bibel et al., 2004) and profiled the miRNA expression
at the beginning and at the end of the protocol. At that point,
this line generated cells with miRNA profiles close to category 1
on miRMap (Figure S4). To gain a better idea of the trajectory of
miRNA profiles in miRMap, we profiled several intermediate
steps along the differentiation of category 3 iPSCs to retinal
progenitors (Lamba et al., 2006). The projections of miRNA
profiles were significantly shifted along classifier r1 at DIV 4
toward category 4 (Figure 6A). The shift along that classifier
was stabilized after DIV 7. We detected a significant shift toward
lineage-committed cells along classifier r2: the shiftwasprogres-
sive starting at DIV 4 to DIV 10 (Figure 6A). The differentiation to
multipotent cells had the overall effect to shift the projection
toward category 2, the class of the neural stem cell sample and
cancer cell lines (Figure 6A). This localization suggests that the
miRNA expression pattern can define multipotent cells and
distinguish them from both pluripotent and terminally differenti-
ated cells. The shared miRNA expression characteristics of
precursor states and cancer are consistent with prior reports
(Pardal et al., 2003) andcan be separatedwith additionalmarkers
such as PC1 miRNAs. Thus, differentiation shifted category 3
iPSCs toward a category 4 miRNA profile before the decrease
of pluripotency-associated miRNA expression occurred.
We then used miRMap classifiers to assess miRNA profiles
during the reprogramming procedure. Reprogramming yieldsl Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Inc. 677
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understood by examining intermediates in reprogramming. A set
of molecular markers can distinguish partially reprogrammed
cells from fully reprogrammed cells, and depending on the
constellation of markers expressed, three types of colonies
have been described (Chan et al., 2009): type I, which did not
express the hESCmarkers SSEA-4 and TRA-1-60; type II, which
expressed only SSEA-4; and type III, which were found to be
bona fide iPSCs. Given the temporal profile of those two hESC
markers and their expression in bona fide iPSCs, type I and II
cells might be considered intermediate states. We profiled
miRNA expression in partially reprogrammed cells of types I
and II and compared them to iPSCs generated concomitantly.
Type I and II cells had a miRNA profile akin to categories 2 and
4 along classifier r1 (Figure 6B). These cells were scattered along
classifier r2 between categories 2 and 4. Because reprogram-
ming involves the gain of pluripotency features and the loss of
differentiation features, we lookedmore closely at miRNAs asso-
ciated with those two states. Expression of the miR-302 and
miR-371 clusters—miRNAs under the transcriptional control of
OCT4—was turned on gradually; however, miRNAs in the chro-
mosome 19q13.42 cluster that are not under the transcriptional
control of OCT4 were expressed only in one type II sample and
the two iPSC lines (Figure S5). Expression of the let-7 family in
partially reprogrammed cells was comparable to that in fibro-
blasts and was downregulated only in the two iPSC lines. Over-
all, only cells possessing the ability to form teratomas had similar
expression levels of pluripotency- and differentiation-associated
miRNAs as hESCs. We also investigated whether partially
reprogrammed cells had a distinct miRNA expression pattern
not captured in miRMap. We quantified changes along the
largest degree of miRNA variation by projecting the miRNA
profiles on PC1 (Figure 6C). Types I and II were significantly
shifted toward cancer cells. This shift is only transient; iPSCs
from this data set were significantly shifted back. Therefore re-
programming appears to follow a preferred route through cate-
gories 4- and 2-type miRNA expression profiles. Because during
differentiation, the profiles also resembled a category 4 profile,
this category positions itself as an attractor state that miRNA
profiles transfer through during both reprogramming and differ-
entiation to progenitors.
DISCUSSION
We profiledmiRNA expression in a large number of human hESC
and iPSC to test the variability of the pluripotent state. We found
that variation in miRNA expression across many different human
iPSCs and hESCs was comparable to the variability across a set
of differentiated and cancer cells. miRNA profiles of pluripotent
cells fall into two distinct categories that did not depend on
whether cells were reprogrammed from a somatic cell or came
from an embryo. Instead, these two pluripotent stem cell states
differ in the expression of a group of miRNAs that also classify
cancer cells and in the status of their p53 network. Overexpres-
sion of the p53-regulatory miRNAsmiR-92 andmiR-141 in iPSCs
induced a change of miRNA profile class. We defined a two-
dimensional representation of miRNA expression, the miRMap,
that makes it possible to examine differentiation and reprogram-
ming in a quantitative way.678 Cell Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier IncPrevious studies on iPSCs have reported a downregulation of
themiR-371 family compared to hESCs (Wilson et al., 2009; Chin
et al., 2009); however, this feature does not appear to be a hall-
mark of iPSCs. Indeed, two of the six hESC lines that we profiled
had the iPSC signature reported by Wilson et al. (2009) and Chin
et al. (2009) and three iPSCs did not. Instead, we found that
pluripotent cells can be distinguished based on the expression
of 11 miRNAs that also classify cancer versus differentiated
cells. Those miRNAs included miR-199a* and miR-302a, which
target proproliferative cyclins (Card et al., 2008) and oncogenes
(Migliore et al., 2008).
At least two pathways important for tumor progression impact
the levels of miRNAs associated with the main component of
variation in miRNA expression in pluripotent and lineage-
committed cells, PC1. Loss of p53 changed the MEF miRNA
profile into a cancer-like one. Activation of the PI3K/Akt/mTOR
pathway through loss of Tsc2 in a p53/ background shifted
the miRNA profile even further on PC1. This pathway, which is
dysregulated in many human cancers (Luo et al., 2003), plays
a key role in cell proliferation and growth and is also connected
to the p53 pathway (Feng et al., 2005). Thus PC1-associated
miRNAs may control cell cycle progression and cell proliferation
(Mendell, 2008).
ThemiRMap can also reveal reprogramming networks as cells
lose their differentiated features and acquire an hESC-like chro-
matin state and transcription profile. For example, p53 KO in
fibroblasts, which can increase reprogramming efficiency, drove
the miRNA profile in the same direction as the partially reprog-
rammed cells, i.e., toward category 2 on miRMap and cancer-
like expression along PC1. Reprogramming intermediates
corresponding to types I and II all exhibited similar expression
levels of differentiation-associated miRNAs as fibroblasts.
Some of them expressed pluripotency-associated miRNAs,
but at intermediate levels compared to bona fide iPSCs. The
miR-302 and miR-371 clusters exhibited a similar expression
profile across reprogramming intermediates and share OCT4
binding sites in their promoter regions (Marson et al., 2008),
but miRNAs in the chromosome 19q13.42 cluster were ex-
pressed only in cells with high miR-302 and miR-371 expression
and, interestingly, their promoter is not occupied by OCT4. The
downregulation of differentiation-associated miRNAs occurred
only in bona fide iPSCs. The silencing of differentiation-associ-
ated genomic regions occurs at a later stage (Kim et al., 2010),
consistent with our observations that the gain of pluripotency-
associated markers during reprogramming precedes the
silencing of differentiation-associated miRNAs. Moreover,
partially reprogrammed cells also exhibited expression of PC1-
associated miRNAs similar to that seen in cancer cells, which
is consistent with their high total MYC expression compared to
iPSCs (Chan et al., 2009).
The miRNA profiles of reprogramming intermediates suggest
that differentiated cells first need a critical alteration of their
controls over growth and proliferation before gaining features
of pluripotency. This conclusion is in line with the temporal
requirement of the reprogramming factors in mouse cells
(Sridharan et al., 2009): MYC expression is needed at early
stages (Singh and Dalton, 2009), whereas OCT4 and SOX2,
transcription factors associated with pluripotency, are needed
at later stages. Indeed, the miR-17–92 cluster is under.
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miRNAs Define Two p53-Linked Pluripotent Statestranscriptional control of MYC (O’Donnell et al., 2005), and MYC
overexpression leads to increased levels of miR-92 with
a concomitant shift of the miRNA profile along PC1 and classifier
r1. Moreover, classification of pluripotency occurs along an axis
of miRNAs (miR-302 family and themiR-371/372/373 family) that
have their promoters occupied by OCT4 in hESCs (Marson et al.,
2008). Thus the miRMap trajectory of reprogramming intermedi-
ates supports an early role for MYC followed by the action of
OCT4. Interestingly, bona fide iPSCs showed a shift in miRNA
expression away from cancer cells that coincided with a downre-
gulation ofMYC transcript levels. This observation suggests that
the alteration of proliferation and cell cycle controls is only a tran-
sient event during the reprogramming process.
In summary, we have shown that miRNA profiles reveal signif-
icant diversity among human pluripotent cells and clustering
into two categories based on the expression of a collection of
miRNAs, that also distinguish cancer cells from differentiated
cells. This dichotomy does not depend on the origin of the cells
as iPSCs or hESCs, but instead depends on the status of the p53
network and suggests a potential subdivision of phenotypes for
the pluripotent state.
EXPERIMENTAL PROCEDURES
Cell Lines
Assayed pluripotent cells can be found in Table 1. Assayed differentiated cells
were the fibroblast lines CCD-1079SK, IMR90, Hs27, fetal brain tissue, adult
brain tissue, and lung tissue. Assayed cancer lines were HeLa, TC-71, HT-
29, Daoy, U-87 MG, PANC-1, PC-3, Hep G2, D283 Med (ATCC). Glioma bio-
psies were proviously described (Liu et al., 2007). Neural stem cells were
obtained as previously described (Hemmati et al., 2003). Profiled mouse cell
lines were the fibroblast lines MEF, p53/ MEF, and p53/Tsc2/ MEF
and the cancer lines Neuro2A and B16.
Cell Culture
hESCs (WiCell or ES Cell International) were grown on Hs27 human feeder
cells in DMEM/F12/GlutaMAX I with 20% Knockout Serum Replacement,
0.1mMMEMNonessential amino acids (NAA), 0.1 mM b-mercaptoethanol (In-
vitrogen), and 4 ng/ml bFGF (Peprotech). Mitotically inactivated Hs27 (mito-
mycin C, Sigma) were cultured on gelatin-coated plates in DMEM medium
with 10% FBS and 4 mM GlutaMAX I (Invitrogen). IPSCs were grown on
MEF (mouse embryonic fibroblast) with 100 ng/ml zFGF (a gift from J. Thom-
son) in the same culture media. Mitotically inactivated MEF were cultured on
gelatin-coated plates in DMEM medium with 10% FBS and NAA (Invitrogen).
hESCs and iPSCs were passed every week with the ‘‘pick to keep’’ procedure.
In brief, colonies were physically dissected with small pipette tips and
transferred to new plates at a 1:3 to 1:6 ratio. IMR90 was cultured in MEM
with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 0.1 mM NAA, 1.0 mM
sodium pyruvate, and 10% FBS. CCD was cultured in MEM with 10% FBS.
All cell lines had a normal karyotype (Cell Line Genetics).
Differentiation to Retinal Progenitors
iPSCs were differentiated to retinal progenitors via a previously described
method (Lamba et al., 2006). We collected RNA samples at days 4, 7, and
10 of the differentiation protocol.
Infection of iPSCs with miRNA-Expressing Lentivirus
Lentiviral particles expressing miRNA (System Biosciences) were produced
with Lentiviral Packaging Kit (SBI). iPSCs were preincubated 1 hr with 1 mM
ROCK inhibitor (Y-23672, Calbiochem) (Watanabe et al., 2007), dissociated
with Non-Enzymatic Cell Dissociation Solution (GIBCO) to single cell, and
virally infected in suspension (MOI 1). After 1 hr, cells were plated on MEF.
Cells were cultured with Y-23672 for 2 days. Individual colonies were
expanded by physical dissection.CelRNA Extraction and Multiplexed PCR
Total RNA was extracted with miRVana miRNA Isolation Kit (Ambion). RNA
amount was quantified with Nanodrop (Thermo Scientific) and reverse tran-
scribed (ABI). miRNAs were quantified with Taqman-based method and
mRNAs with Power Sybrgreen (ABI). Details can be found in Supplemental
Information.
Data Analysis
Data analysis was done with Python scripts via SciPy, NumPy, and MDP (Zito
et al., 2009)modules and the NMF version described in Lin (2007). An outline of
the data analysis procedure is provided in Supplemental Information.
Normalization
Ct values for each sample are globally normalized with Ct values < 25. miRNA
with aCt value < 30 in at least one sample and showing at least a 2-fold expres-
sion change across all samples (308 out of 330 tested) were kept for further
analysis.
Determination of the Number of Clusters
We used Nonnegative Matrix Factorization (NMF) as an unsupervised way to
cluster the miRNA profiles. NMF was computed on miRNA expression profiles
on a log2 scale of 6 hESCs, 16 iPSCs, 6 differentiated cells, and 9 cancer cell
lines. For each miRNA, the mean expression level across those samples was
subtracted and the variance was normalized to one. We determined the
minimum number of metaprofiles necessary to separate pluripotent cells
from differentiated cells from cancer cells. Clustering was determined accord-
ing to Brunet et al. (2004): for each number of metaprofiles, we determined the
consensus matrix as the average connectivity matrix over 1000 clustering
runs.
Principal Component Analysis
The principal components shown were computed with miRNA profiles (with
expression levels as Ct values) from all the pluripotent, differentiated, and
cancer cells (37 profiles total). The miRNA profile for line j consisted of Ct
values {xi
j} for the associated miRNAs {mi}. PCA determined PCs components
{Xa} corresponding to the set of eigenvalues {la} of the covariance matrix. For
the cell line j, we plotted the projection on the ath PC weighted by the square
root of the associated eigenvalue: 1=
ﬃﬃﬃﬃﬃ
la
p ðxj  xÞ$Xa where x was the mean
miRNA profile averaged on all cell lines.
Analysis of Gene Expression Data
Gene expression data of episome-induced iPSC, virus-induced iPSC and
hESC was obtained from NCBI Gene Expression Omnibus database under
the accession numbers GSE9164 (Yu et al., 2007) and GSE15148 (Yu et al.,
2009). We performed GSEA analysis (Subramanian et al., 2005) with the
curated gene sets (canonical pathways, BioCarta, GenMAPP and KEGG)
and the cancer modules from the computational gene sets. To determine
enrichment-associated p values, we identified transcripts differentially
expressed between categories 3 and 4. We discarded all probes with less
than 2-fold expression change across all samples and determined transcripts
significantly dysregulated via two-tailed t test corrected formultiple hypothesis
testing according to Benjamini and Hochberg (1995). p values were empirically
estimated by comparing the enrichment of dysregulated genes in a particular
gene set to the enrichment distribution determined by resampling the probe
set 10,000 times, followed bymultiple hypothesis correction. Significance level
was set at 0.05. We compared significantly dysregulated genes in episome-
induced iPSCs compared to hESCs to the list of 129 genes under transcrip-
tional control by p53 provided by Riley et al. (2008). 53 genes were significantly
dysregulated (30 genes expected with a random set).
Determination of the Linear Classifiers Defining miRMap
The two linear classifiers defining miRMap were determined with Support
vector machine as being the two orthogonal directions along which the
distances between the four miRNA expression categories were maximized.
Robustness of the classifiers was determined by constructing the classifiers
on training sets comprising three cell lines chosen at random for each category
and with the remaining 42 samples as a validation set. 10,000 iterations werel Stem Cell 7, 671–681, December 3, 2010 ª2010 Elsevier Inc. 679
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99.9% along classifier r2.
Adaptation of miRMap to Microarray Data
For a given microarray, we restricted the linear classifiers defining miRMap to
the miRNAs with probes found in our RT-PCR set. We computed the mean
signal of all the probes assaying the same miRNA. We analyzed data obtained
on the Agilent-016436 Human miRNA Microarray 1.0 (GEO accession
numbers GSE11806 [Ach et al., 2008], GSE14473 [Stadler et al., 2010]), on
the OSUCCC Human miRNA Expression custom Bioarray (GSE16654 [Chin
et al., 2009]), data obtained from bead-based profiling (GSE2564 [Lu et al.,
2005]), and data from microarray profiling (Laurent et al., 2008). Projections
on the classifiers were computed with the logarithm of the probe signals. To
combine projections from different platforms, we normalized them by the
detection range of the microarray.
Determination of p Values Associated with miRMap Projections and
Projection onto PC1 of miRNA Profiles
To associate a p value with the movement of samples along r1, r2, and PC1,
we used the spread of the projections ofmiRNAprofiles of biological replicates
onto each axis. The degree of movement necessary to yield a p value < 0.05 for
each axis was defined as theminimum distance d for which 95% of the biolog-
ical replicates had a distance between projections smaller than d.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
data analysis overview, four figures, one table, one miRNA expression file,
and two files with the miRMap classifiers for our data and eight microarray
platforms and can be found with this article online at doi:10.1016/j.stem.
2010.11.012.
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